MedTrace Logo

ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months

NCT01091740 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-01-31

No results posted yet for this study

Summary

This study try to 1) evaluate the neointimal coverage and malapposition at 3 month after new zotarolimus eluting stent (Endeavor resolute) and everolimus eluting stent (Xience) implantation and 2) compare them between ZES resolute and EES at 3 months (early period) after stent implantation.

Conditions

Interventions

DEVICE

ZES resolute (Endeavor Resolute)

2nd generation drug eluting stent, which is coated with zotarolimus

DEVICE

EES (Xience)

2nd generation drug eluting stent, which is coated with everolimus

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Principal Investigators

  • Jung-Sun Kim, MD, Ph D · Division of Cardiology, Cardiovascular Hospital, Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01091740 on ClinicalTrials.gov